RNA Formulation Resources
-
Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications
4/18/2022
Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.
-
What Established Modalities Can Teach Us About Manufacturing In Vivo CAR-T
10/27/2026
In vivo CAR-T manufacturing can build on established mRNA-LNP and cell therapy platforms, but requires tailored controls linking formulation attributes, targeted delivery, functional potency, stability, and scalable production.
-
Optimizing Leukapheresis Cryopreservation For CGT
6/3/2025
Discover how an automated cryopreservation process is reshaping the leukapheresis supply chain and driving progress in the future of cell and gene therapy.
-
Exploring Osmolality As A CQA Within RNA Therapeutics
10/3/2023
Discover how osmolality can be applied throughout the bioprocessing workflow for RNA, and recognize the importance of this sensitive measurement, from formulation optimization to cryopreservation techniques.
-
Transferring From Microfluidics To A Turbulent Mixer
4/18/2024
What solutions did the client featured in this case study find when they sought help in transferring their formulation process to a turbulent Impinged Jet Mixing (IJM)?
-
Boost LNP Drug Potency With Optimized Delivery Formulations
11/21/2022
Lipid nanoparticles (LNPs) function as a drug delivery system for nucleic acids. Learn about the biomedical applications of LNPs as well as the anatomy, formulation optimization, and safety of LNPs.
-
The Importance Of Linear Scalability In Nanoparticle Processing
10/14/2025
Learn how turbulent jet mixing enables linear scalability, guaranteeing consistent nanoparticle quality from research to commercial production and accelerating product timelines.
-
Expectations On The Pathway To GMP For Gene-Modified Cell Therapies
6/21/2023
Learn how a robust understanding of the RNP’s critical process parameters and CQAs is crucial for ensuring product consistency, enhancing patient safety, and maintaining regulatory compliance.
-
Is Standardization The Key To Scalable CGT?
3/2/2026
Experts note CGT programs often struggle due to limited operational readiness; early standardization supports scalable, reproducible, regulatory‑ready development and helps prevent late‑stage bottlenecks.
-
Enabling Continuous Manufacturing For CAR-T And LNP-Based Therapies
6/27/2025
Breakthrough therapies are challenged by complex, batch-based manufacturing. A novel, integrated system enables continuous processing, improving consistency and reducing manual handling for advanced modalities.